SG170073A1 - Long term treatment of hiv infection - Google Patents

Long term treatment of hiv infection

Info

Publication number: SG170073A1
Authority: SG; Singapore
Prior art keywords: long term; hiv infection; term treatment; formulation; treatment
Prior art date: 2006-01-20

Application number

SG201101585-6A

Other languages

English (en)

Inventor

Lieven Elvire Colette Baert

Guenter Kraus

Aet Klooster Gerben Albert Eleutherius Van

Original Assignee

Tibotec Pharm Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-01-20

Filing date

2007-01-19

Publication date

2011-04-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36446113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG170073(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-01-19 Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd

2011-04-29 Publication of SG170073A1 publication Critical patent/SG170073A1/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Virology (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG201101585-6A 2006-01-20 2007-01-19 Long term treatment of hiv infection SG170073A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP06100677		2006-01-20

Publications (1)

Publication Number	Publication Date
SG170073A1 true SG170073A1 (en)	2011-04-29

Family

ID=36446113

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG201101585-6A SG170073A1 (en)	2006-01-20	2007-01-19	Long term treatment of hiv infection

Country Status (27)

Country	Link
US (4)	US10953009B2 (es)
EP (1)	EP1981506B3 (es)
JP (2)	JP5754005B2 (es)
KR (2)	KR101562943B1 (es)
CN (2)	CN103877091A (es)
AP (1)	AP2936A (es)
AR (1)	AR059097A1 (es)
AU (1)	AU2007206901B2 (es)
BR (1)	BRPI0707179A2 (es)
CA (1)	CA2636436C (es)
CY (1)	CY1114089T1 (es)
DK (1)	DK1981506T6 (es)
EA (1)	EA014914B1 (es)
ES (1)	ES2414982T7 (es)
HR (1)	HRP20130544T4 (es)
IL (1)	IL192132A (es)
ME (1)	ME01617B (es)
MY (1)	MY150717A (es)
NZ (1)	NZ569347A (es)
PL (1)	PL1981506T6 (es)
PT (1)	PT1981506E (es)
RS (1)	RS52821B2 (es)
SG (1)	SG170073A1 (es)
SI (1)	SI1981506T1 (es)
TW (1)	TWI458483B (es)
UA (1)	UA96436C2 (es)
WO (1)	WO2007082922A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
TWI457136B (zh) *	2005-04-04	2014-10-21	Tibotec Pharm Ltd	Ｈｉｖ-感染之預防
JP5754005B2 (ja)	2006-01-20	2015-07-22	ヤンセン・アールアンドデイ・アイルランド	Ｔｃｍ２７８を用いるｈｉｖ−感染症の長期間処置
AR061620A1 (es)	2006-06-23	2008-09-10	Tibotec Pharm Ltd	Suspensiones acuosas de tmc278
AU2014200819B2 (en) *	2006-06-23	2016-05-26	Janssen Sciences Ireland Uc	Aqueous suspensions of TMC278
AU2016219555B2 (en) *	2006-06-23	2017-08-10	Janssen Sciences Ireland Uc	Aqueous suspensions of TMC278
TWI494133B (zh)	2007-03-14	2015-08-01	Tibotec Pharm Ltd	重組用粉末
ES2607107T3 (es) *	2008-12-24	2017-03-29	Janssen Sciences Ireland Uc	Dispositivos implantables para tratar el VIH
BR112012006345A2 (pt) *	2009-09-22	2020-08-11	Tibotec Pharmaceuticals	tratamento e prevenção de infecção de hiv
MX2012007210A (es)	2009-12-21	2012-07-23	Janssen R & D Ireland	Implante removible degradable para la liberacion sostenida de un compuesto activo.
SMT201800290T1 (it) *	2010-01-27	2018-07-17	Viiv Healthcare Co	Terapia antivirale
TWI577377B (zh) *	2010-09-16	2017-04-11	Ｖｉｉｖ醫療保健公司	醫藥組合物
US9266824B2 (en)	2014-01-13	2016-02-23	Warsaw Orthopedic, Inc.	Methods and compositions for making an amino acid triisocyanate
US10406098B2 (en) *	2015-11-16	2019-09-10	Evonik Roehm Gmbh	Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide)
US20190163877A1 (en) *	2017-11-27	2019-05-30	International Business Machines Corporation	Decision support for effective long-term drug therapy
WO2022079739A1 (en)	2020-10-14	2022-04-21	Cipla Limited	Fixed dose compositions of cabotegravir and rilpivirine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
JPH06316524A (ja)	1992-09-11	1994-11-15	Naoyuki Inoue	抗エイズウイルス剤
US6045829A (en)	1997-02-13	2000-04-04	Elan Pharma International Limited	Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
UA72189C2 (uk)	1997-11-17	2005-02-15	Янссен Фармацевтика Н.В.	Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6258932B1 (en)	1999-08-09	2001-07-10	Tripep Ab	Peptides that block viral infectivity and methods of use thereof
EP1214059B1 (en)	1999-09-21	2005-05-25	Skyepharma Canada Inc.	Surface modified particulate compositions of biologically active substances
MXPA02009534A (es)	2000-03-30	2003-05-14	Squibb Bristol Myers Co	Granulos de liberacion sostenida que contienen estavudina.
US20040115268A1 (en)	2000-04-26	2004-06-17	Control Delivery Systems, Inc.	Systemic delivery of antiviral agents
JO3429B1 (ar) *	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en)	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
US20030166509A1 (en)	2001-11-20	2003-09-04	Advanced Inhalation Research, Inc.	Compositions for sustained action product delivery and methods of use thereof
US6568805B1 (en) *	2001-11-26	2003-05-27	Dan L. Dietz Trust	Magnetic buckle for eyeglasses
EP1525216A4 (en) *	2002-01-24	2009-07-08	Sangstat Medical Corp	COMBINATION THERAPY FOR THE TREATMENT OF HIV INFECTION
AU2003291457A1 (en)	2002-11-08	2004-06-03	Glaxo Group Limited	Pharmaceutical antiviral compositions
CN1809378B (zh)	2002-11-18	2010-06-23	德西涅Rx制药公司	体内抑制病毒复制的方法
NZ541902A (en)	2003-02-07	2008-12-24	Janssen Pharmaceutica Nv	Pyrimidine derivatives for the prevention of HIV infection
US20040180893A1 (en)	2003-02-21	2004-09-16	Balzarini Jan Maria Rene	Identification of compounds that inhibit replication of human immunodeficiency virus
WO2006024668A1 (en) *	2004-09-02	2006-03-09	Janssen Pharmaceutica N.V.	Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
DK1632232T6 (da) *	2004-09-02	2022-04-19	Janssen Pharmaceutica Nv	Salt af 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]¬amino]¬benzonitril
KR20130030305A (ko)	2004-11-16	2013-03-26	엘란 파마 인터내셔널 리미티드	주사가능한 나노입자형 올란자핀 제형
TWI457136B (zh)	2005-04-04	2014-10-21	Tibotec Pharm Ltd	Ｈｉｖ-感染之預防
JP5754005B2 (ja)	2006-01-20	2015-07-22	ヤンセン・アールアンドデイ・アイルランド	Ｔｃｍ２７８を用いるｈｉｖ−感染症の長期間処置
AR061620A1 (es)	2006-06-23	2008-09-10	Tibotec Pharm Ltd	Suspensiones acuosas de tmc278
HRP20131128T1 (hr)	2007-07-12	2013-12-20	Janssen R&D Ireland	Kristalni oblik (e) 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila

2007
- 2007-01-19 JP JP2008550764A patent/JP5754005B2/ja active Active
- 2007-01-19 PT PT77120533T patent/PT1981506E/pt unknown
- 2007-01-19 RS RS20130258A patent/RS52821B2/sr unknown
- 2007-01-19 AR ARP070100247A patent/AR059097A1/es not_active Application Discontinuation
- 2007-01-19 TW TW096101983A patent/TWI458483B/zh active
- 2007-01-19 CN CN201410126123.XA patent/CN103877091A/zh active Pending
- 2007-01-19 CN CNA2007800024269A patent/CN101370504A/zh active Pending
- 2007-01-19 MY MYPI20082697 patent/MY150717A/en unknown
- 2007-01-19 CA CA2636436A patent/CA2636436C/en active Active
- 2007-01-19 ES ES07712053T patent/ES2414982T7/es active Active
- 2007-01-19 SI SI200731253T patent/SI1981506T1/sl unknown
- 2007-01-19 AP AP2008004535A patent/AP2936A/xx active
- 2007-01-19 SG SG201101585-6A patent/SG170073A1/en unknown
- 2007-01-19 BR BRPI0707179-5A patent/BRPI0707179A2/pt not_active Application Discontinuation
- 2007-01-19 EP EP07712053.3A patent/EP1981506B3/en active Active
- 2007-01-19 NZ NZ569347A patent/NZ569347A/en unknown
- 2007-01-19 EA EA200870183A patent/EA014914B1/ru unknown
- 2007-01-19 US US12/161,445 patent/US10953009B2/en not_active Ceased
- 2007-01-19 KR KR1020147030400A patent/KR101562943B1/ko active Active
- 2007-01-19 DK DK07712053.3T patent/DK1981506T6/da active
- 2007-01-19 ME MEP-2013-66A patent/ME01617B/me unknown
- 2007-01-19 WO PCT/EP2007/050516 patent/WO2007082922A2/en not_active Ceased
- 2007-01-19 PL PL07712053T patent/PL1981506T6/pl unknown
- 2007-01-19 HR HRP20130544TT patent/HRP20130544T4/hr unknown
- 2007-01-19 KR KR1020087018888A patent/KR101501475B1/ko active Active
- 2007-01-19 AU AU2007206901A patent/AU2007206901B2/en active Active
- 2007-01-19 US US17/473,424 patent/USRE50189E1/en active Active
- 2007-01-19 UA UAA200809750A patent/UA96436C2/ru unknown
2008
- 2008-06-12 IL IL192132A patent/IL192132A/en active IP Right Grant
2013
- 2013-01-28 JP JP2013013118A patent/JP5836983B2/ja active Active
- 2013-06-27 CY CY20131100521T patent/CY1114089T1/el unknown
2021
- 2021-03-01 US US17/188,850 patent/US20210177843A1/en not_active Abandoned
2023
- 2023-08-22 US US18/236,734 patent/US20240226099A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PT1981506E (pt)	2013-06-25
CY1114089T1 (el)	2016-07-27
EP1981506B3 (en)	2021-06-09
RS52821B (sr)	2013-10-31
RS52821B2 (sr)	2021-07-30
AP2936A (en)	2014-07-31
SI1981506T1 (sl)	2013-08-30
ES2414982T3 (es)	2013-07-23
NZ569347A (en)	2011-07-29
EA200870183A1 (ru)	2009-12-30
BRPI0707179A2 (pt)	2011-04-26
PL1981506T6 (pl)	2021-07-12
CA2636436A1 (en)	2007-07-26
HK1125828A1 (en)	2009-08-21
KR20140141699A (ko)	2014-12-10
DK1981506T6 (da)	2021-06-14
AU2007206901B2 (en)	2013-01-31
HRP20130544T1 (en)	2013-07-31
CN103877091A (zh)	2014-06-25
AU2007206901A1 (en)	2007-07-26
AP2008004535A0 (en)	2008-08-31
JP5836983B2 (ja)	2015-12-24
JP5754005B2 (ja)	2015-07-22
MY150717A (en)	2014-02-28
ME01617B (me)	2014-09-20
HRP20130544T4 (hr)	2021-08-20
USRE50189E1 (en)	2024-10-29
AR059097A1 (es)	2008-03-12
ES2414982T7 (es)	2021-11-05
EA014914B1 (ru)	2011-02-28
EP1981506B1 (en)	2013-03-27
US10953009B2 (en)	2021-03-23
TWI458483B (zh)	2014-11-01
WO2007082922A8 (en)	2008-01-03
IL192132A (en)	2014-05-28
US20240226099A1 (en)	2024-07-11
US20210177843A1 (en)	2021-06-17
WO2007082922A2 (en)	2007-07-26
US20110275654A1 (en)	2011-11-10
DK1981506T3 (da)	2013-06-24
PL1981506T3 (pl)	2013-08-30
JP2013100338A (ja)	2013-05-23
UA96436C2 (ru)	2011-11-10
KR101501475B1 (ko)	2015-03-19
CA2636436C (en)	2014-04-01
EP1981506A2 (en)	2008-10-22
KR20080085194A (ko)	2008-09-23
WO2007082922A3 (en)	2007-09-20
KR101562943B1 (ko)	2015-10-23
CN101370504A (zh)	2009-02-18
TW200806295A (en)	2008-02-01
IL192132A0 (en)	2009-08-03
JP2009526758A (ja)	2009-07-23

Publication	Publication Date	Title
SG170073A1 (en)	2011-04-29	Long term treatment of hiv infection
JOP20200160A1 (ar)	2022-10-30	محاليل معلقة مائية للمركبات المسمى تي ام سي 278
MX2009006764A (es)	2009-11-26	Pirimidinonas biciclicas y usos de la misma.
ZA202002139B (en)	2024-02-28	Combination pharmaceutical agents as rsv inhibitors
PH12014500386A1 (en)	2019-10-07	Combination treatment for hepatitis c
WO2008054454A3 (en)	2008-10-09	Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
NZ627824A (en)	2016-02-26	Antiviral combinations involving (4r,12as)-n-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2hpyrido[1’,2’:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
NZ616806A (en)	2015-03-27	Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
MX2012007410A (es)	2012-07-17	Compuestos antivirales novedosos.
MX2013005478A (es)	2013-08-29	Compuestos heterociclicos condensados antivirales.
UA96449C2 (en)	2011-11-10	Stable laquinimod preparations
NZ582089A (en)	2013-01-25	Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
TW200510425A (en)	2005-03-16	Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
NZ595313A (en)	2013-03-28	The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
MX2010008921A (es)	2010-09-07	Derivados de oxazolidinona.
WO2005089738A3 (en)	2007-08-23	Use and administration of bacterial efflux pump inhibitors
MX336657B (es)	2016-01-27	Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.
NZ600912A (en)	2014-05-30	Topical use of hydroxytyrosol and derivatives for the prevention of hiv infection
BRPI0920605A2 (pt)	2015-12-22	composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste.
UA90124C2 (ru)	2010-04-12	Способ профилактики вич-инфекции с помощью тмс278
WO2012024363A3 (en)	2012-05-31	Compounds and methods for the treatment or prevention of flaviviridae viral infections
NZ542305A (en)	2009-03-31	Treatment of proliferative diseases with an epothilone derivative and radiation
WO2010033219A3 (en)	2010-06-03	Protease inhibitors having enhanced features
GB0229022D0 (en)	2003-01-15	Organic Compounds
WO2011036159A3 (en)	2011-11-24	Treatment and prevention of hiv infection